用于胰腺癌高特异性诊断的粪便微生物群特征
本研究通过西班牙病例对照研究(n=136,含57例胰腺导管腺癌、50例对照、29例慢性胰腺炎)和德国验证研究(n=76),采用鸟枪法宏基因组与16S rRNA测序分析粪便和唾液微生物群。基于27种微生物的粪便分类器诊断胰腺导管腺癌的AUROC最高达0.84,联合CA19-9后提升至0.94,且在德国验证人群中预测准确率高。
要点
- 粪便微生物分类器诊断胰腺导管腺癌的AUROC最高达0.84。
- 联合CA19-9后AUROC提升至0.94。
- 微生物模型在德国验证人群(n=76)中预测准确率高。
核心结论
- 研究结果表明,基于粪便微生物群的非侵入性、稳健且特异的胰腺导管腺癌早期筛查是可行的。
研究设计与样本
- 西班牙病例对照研究(n=136)包含57例胰腺导管腺癌、50例对照和29例慢性胰腺炎患者,用于发现阶段。
- 德国病例对照研究(n=76)用于验证阶段。
- 采用鸟枪法宏基因组测序和16S rRNA扩增子测序分析粪便和唾液样本。
主要发现
- 粪便宏基因组分类器表现远优于唾液分类器,基于27种微生物的诊断胰腺导管腺癌的AUROC最高达0.84,在早期和晚期疾病阶段准确率一致。
- 将微生物群预测与血清CA19-9水平联合后,AUROC最高提升至0.94;CA19-9是当前唯一获美国食品药品监督管理局批准的非侵入性、低特异性胰腺导管腺癌诊断生物标志物。
- 基于胰腺导管腺癌富集物种的微生物分类模型在针对25个公开宏基因组研究人群(n=5792)进行验证时,显示出高度的疾病特异性。
- 两种基于微生物组的模型在德国验证人群(n=76)中均具有高预测准确率。
- 使用16S rRNA测序和荧光原位杂交,在胰腺肿瘤和非肿瘤组织中可检测到若干粪便胰腺导管腺癌标志物种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent evidence suggests a role for the microbiome in pancreatic ductal adenocarcinoma (PDAC) aetiology and progression. OBJECTIVE: To explore the faecal and salivary microbiota as potential diagnostic biomarkers. METHODS: We applied shotgun metagenomic and 16S rRNA amplicon sequencing to samples from a Spanish case-control study (n=136), including 57 cases, 50 controls, and 29 patients with chronic pancreatitis in the discovery phase, and from a German case-control study (n=76), in the validation phase. RESULTS: Faecal metagenomic classifiers performed much better than saliva-based classifiers and identified patients with PDAC with an accuracy of up to 0.84 area under the receiver operating characteristic curve (AUROC) based on a set of 27 microbial species, with consistent accuracy across early and late disease stages. Performance further improved to up to 0.94 AUROC when we combined our microbiome-based predictions with serum levels of carbohydrate antigen (CA) 19-9, the only current non-invasive, Food and Drug Administration approved, low specificity PDAC diagnostic biomarker. Furthermore, a microbiota-based classification model confined to PDAC-enriched species was highly disease-specific when validated against 25 publicly available metagenomic study populations for various health conditions (n=5792). Both microbiome-based models had a high prediction accuracy on a German validation population (n=76). Several faecal PDAC marker species were detectable in pancreatic tumour and non-tumour tissue using 16S rRNA sequencing and fluorescence in situ hybridisation. CONCLUSION: Taken together, our results indicate that non-invasive, robust and specific faecal microbiota-based screening for the early detection of PDAC is feasible.
引用
- Kartal E, Schmidt TSB, Molina-Montes E, et al. A faecal microbiota signature with high specificity for pancreatic cancer. Gut. 2022. PMID: 35260444. doi:10.1136/gutjnl-2021-324755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。